Daniela Sugg

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 8

Top Topics

Replacement Therapy

Radical Prostatectomy

Top Venues

PharmacoEconomics - open

This page only lists publications with an associated author ORCID identifier.

Publications

Carlos Rojas-Roque, Constanza Silvestrini, Fernando J Argento, Daniela Sugg, Federico Augustovski, Jesica Coelli, Natalia Espinola
Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina. PharmacoEconomics - open 8 (4) (2024)
Carlos Rojas-Roque, Constanza Silvestrini, Fernando J Argento, Daniela Sugg, Federico Augustovski, Jesica Coelli, Natalia Espinola
Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina. PharmacoEconomics - open 8 (4) (2024)
Natalia Espinola, Constanza Silvestrini, Carla Colaci, Daniela Sugg, Carlos Rojas-Roque, Jesica Coelli, Federico Augustovski
Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina. PharmacoEconomics - open 8 (5) (2024)
Natalia Espinola, Constanza Silvestrini, Carla Colaci, Daniela Sugg, Carlos Rojas-Roque, Jesica Coelli, Federico Augustovski
Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina. PharmacoEconomics - open 8 (5) (2024)
Natalia Espinola, Constanza Silvestrini, Carla Colaci, Daniela Sugg, Carlos Rojas-Roque, Jesica Coelli, Federico Augustovski
Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina. PharmacoEconomics - open 8 (5) (2024)
Natalia Espinola, Constanza Silvestrini, Carla Colaci, Daniela Sugg, Carlos Rojas-Roque, Jesica Coelli, Federico Augustovski
Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina. PharmacoEconomics - open (2024)
Carlos Rojas-Roque, Constanza Silvestrini, Fernando J Argento, Daniela Sugg, Federico Augustovski, Jesica Coelli, Natalia Espinola
Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina. PharmacoEconomics - open (2024)
Carlos Rojas-Roque, Constanza Silvestrini, Fernando J Argento, Daniela Sugg, Federico Augustovski, Jesica Coelli, Natalia Espinola
Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina. PharmacoEconomics - open 8 (4) (2024)